Thus, the combination of this RNA-based gene signature and IHC findings for p65, SHh and GLI1 may predict the progression of PCa to advanced stages, directing clinicians to focus on this adverse prognostic profile and to consider alternative therapies. Here, GLI1 is linked to posterior cortical atrophy.